1.Disorder of blood pigment in thalasesemia and hemoglobin disease
Journal of Vietnamese Medicine 1999;232(1):30-32
Suming up 1883 hemoglobin electrophoresis patient sample, regardless of age, suspected thalassemia and or Hb disease distributed as following: *-thal: 59.65% including-thalhomozygous: 10.43% -halhomozygous 1.20%, -thal/HbE 29.56% trait 18.46%. *HbE (HbE only and -thal/HbE) 39.66% * thal (HbH and HbH/Hb CS) 27.25%. *HbCS: 7.47%. * and HPFH heterozygous: 2.96%. From these results, it is necessary to up grade the test of quantification of HbA2 and simultanous develop plan of mass screening for thalasemia trait early to identify persons who are at risk of having a child with a severe disease.
Blood
;
Hematologic Diseases
2.Autologus peripheral blood stem transplantation without the cryopreseration in the treatment of the malignant hematologic pathology
Journal of Vietnamese Medicine 1999;232(1):1-11
We performed 10 cases of autologous peripheral blood stem cell transplantation without cryoprevervation in 11/1996 and 12/1997 12. Patients were diagnosed of AML, ALL, CML and non Hodgkin’s lymphoma. The median age of the patients was 34 years (range 18-43). Peripheral blood stem cell mobilizing regiments consisted of Daunorubicine (50 mg/ m2/d, d1-d5) cytarabine and etoposide in 3 CML patients and high dose cyclophosphamide in the seven other patients, followed by G-CSF starting when an ANC< 0.5x 109/l until the day before the last leukapheresis. When a WBC count reached 4x109/l leukapheresis was started and continued for 3 consecutive days, as soon as the third collection was finished Melphalan was given as a conditioning regimen, 42 hours after giving Melphalan, the collected PSCs which were preserved at +40C (90 hours after giving Melphalan, the collected PSCs which were preserved at + 40C were reinfused through a central Hickman’s catheter. GM-CSF was given during the nadir period until the an ANC > 1x109/l for 3 consecutive days. The median number of mononucleated cells and CD34+ cell were 5x108/kg respectively. All platelet count > 20 x 109/l was 13 days and 20 days following transplantation, all patients are still in CR and alive with the median follow-up of 8 months.
Transplantation
;
blood
;
Hematologic Diseases
3.Use of the blood cell seperator for preparation of the platelet for treatment of the malignant hematological diseases
Journal of Vietnamese Medicine 1999;232(1):43-44
The Blood Transfusion and Hematology Center of Ho Chi Minh city used 2,175 units of platelets - prepared by blood cell separator. These clinical results were good and acceptable
Blood Platelets
;
Blood Cells
;
Hematologic Diseases
4.Umbilical Cord Blood Transplantation in Children with Hematologic Diseases.
Korean Journal of Perinatology 2004;15(3):240-244
No abstract available.
Child*
;
Fetal Blood*
;
Hematologic Diseases*
;
Humans
;
Umbilical Cord*
5.A case of fetal hydrops associated with maternal -D-/-D- phenotype.
Jong Yun HWANG ; In Bum SUH ; Jae Yoon SHIM ; Jun Sik CHO ; Dong Hun LEE
Korean Journal of Obstetrics and Gynecology 2006;49(6):1378-1382
Blood types are very important because they are associated with blood transfusion, the diagnosis of hematological diseases and the related diseases. Rh system is a major blood group system as ABO system. Major Rh antigen is Rh (D) antigen. Minor Rh antigens are Rh (C), (c), (E), (e) antigen. Most of people have Rh (C), (c), (E), (e) antigen but some people don't have these antigens. The hematologists call this blood type -D-/-D- blood phenotype. -D-/-D- phenotype is blood group that have (D) antigen without (C), (c), (E), (e) Antigen. This blood type is rare throughout the world. Especially, fetal hydops associated with anti-C,-c,-E,-e antibody is very rare. We experienced a case of fetal hydrops associated with anti-C,-c,-E,-e antibodies and report it with a brief of literatures.
Antibodies
;
Blood Transfusion
;
Diagnosis
;
Hematologic Diseases
;
Hydrops Fetalis*
;
Phenotype*
6.Analysis of Factors Influencing Posttransfusion Effectiveness in 26045 Cases of Platelet Transfusion.
Lin-Feng CHEN ; Ji-Chun PAN ; Qian FENG ; Yuan-Yuan LUO ; Yang YU ; Yuan ZHUANG ; Hui LI ; Yan-Nan FENG ; De-Qing WANG
Journal of Experimental Hematology 2015;23(4):1081-1086
OBJECTIVETo investigate the factors influencing platelet transfusion results so as to improve the platelet transfusion efficiency.
METHODSAccording to the clinical symptoms (bleeding condition is stopped or improved)and the corrected count of increment (CCI), the patients were divided into efficient transfusion and inefficient transfusion groups. A total of 20 671 patients' clinical data and main platelet transfusion parameters in 26 045 tranfusions including platelet count of per- and post- transfusion, platelet component sorts, storage time and transfusion number were analysed.
RESULTSThe comparison of platelet transfusion efficiency in age and sex between two groups did not showed statistical difference (P > 0.05), the platelet count before transfusion between two groups showed statistical difference (t = -5.59, P < 0.001) after converting to log, a significant linear correlation did not exist between storage time of the platelet and CCI (corrected count of increment), but there was statistical difference in transfusion efficiency of patients with different diseases. The patients with hematologic diseases showed lower efficiency of platelet transfusion. According to the results of Wilcocon test detection, there was difference between different times of transfusion and transfusion efficiency, that is to say, the transfusion frequency was higher, the transfusion efficency was lower. The Fisher test indicated that the transfusion efficiency of single platelet transfusion was lower than that of transfussed platelet with other blood components (P < 0.01).
CONCLUSIONPlatelet transfusion efficiency associates with many factors, including different diseases, whether being transfused with other blood components, the platelet count before transfusion, transfusion frequency, but the time of storage does not relate to the transfusion efficacy.
Blood Platelets ; Hematologic Diseases ; Humans ; Platelet Count ; Platelet Transfusion
7.Effects of Siwu tang on serum protein of blood deficiency using proteomic technique.
Ming-Hui YANG ; Zeng-Chun MA ; Yong-Qi DOU ; Jian HU ; Yu-Guang WANG ; Hong-Ling TAN ; Cheng-Rong XIAO ; Yue GAO
China Journal of Chinese Materia Medica 2008;33(4):420-423
OBJECTIVETo research the effects of Siwu tang on serum protein of blood deficiency using proteomic technique and further explore its potential molecular mechanism to cure blood deficiency.
METHODThe sera of normal, blood deficiency and cured group were collected. Proteomic protocol involving the high resolution two-dimensional polyacryamide gel electrophoresis, the computer-assisted image analysis, and the mass spectrometry was used to detect regulated protein by Siwu tang.
RESULTCompared with normal group, there were 15 proteins changed, in which 11 increased and 4 decreased expressed proteins in sera could be recovered by Siwu tang. The up-regulated proteins involved haptoglobin, clusterin, complement component C4B and GTP binding protein 2, while the down-regulated proteins involved transthyretin and heamoglobin beta.
CONCLUSIONSiwu tang could regulate serum protein, which include immunology, apoptosis, DNA injury repair, and blood ingredients. This might be the mechanism of Siwu tang to cure blood deficiency.
Blood Proteins ; drug effects ; Drugs, Chinese Herbal ; pharmacology ; Hematologic Diseases ; blood ; drug therapy ; Humans ; Proteomics ; methods
8.Study on bone marrow microvascular density in hematological diseases.
Wu GAO ; Yan-Qiu SONG ; Wei LI ; Guan-Jun WANG
Journal of Experimental Hematology 2004;12(6):852-854
To investigate the state and significance of bone marrow angiogenesis in hematological diseases, bone marrow microvascular density (BM-MVD) in plastic-embedded section was examined using acetone-fixed bone marrow tissues embedded in glycol-methacrylate (GMA) resin and by the method of immunohistochemistry. The results showed that bone marrow MVD increased greatly in newly diagnosed hematological malignancies before treatment. BM-MVD in patients with acute leukemia decreased down to the normal range as the controls at the time of complete remission. In the non-remission group, BM-MVD decreased less, but when relapsed it increased again up to the same range as the newly diagnosed hematological malignancies, significant increase of BM-MVD was found in patients with anemia, but in less degree than that in hematological malignancies. It is concluded that bone marrow angiogenesis plays a key role in the pathogenesis and development of hematological malignancy. Antiangiogenic therapy may be able to constitute a novel strategy for the treatment of hematological malignancies including leukemia.
Acute Disease
;
Bone Marrow
;
blood supply
;
pathology
;
Hematologic Diseases
;
blood
;
pathology
;
Humans
;
Leukemia
;
blood
;
pathology
;
Microcirculation
;
Neovascularization, Pathologic
;
blood
;
pathology
9.A hundred years after the first article, a recollection: Cabot ring.
Neslihan ERDEM ; Ilhami BERBER ; Ismet AYDOGDU ; Alper SEVINC
The Korean Journal of Internal Medicine 2016;31(1):199-199
No abstract available.
Erythrocytes/*pathology
;
Hematologic Diseases/blood/*diagnosis/history/pathology
;
*Hematology/history/methods
;
History, 20th Century
;
Humans
10.Evaluation of Platelet count by the CELL-DYN Sapphire CD61 Immunoplatelet Method in Patients with Hematologic Diseases Receiving Chemotherapy.
Bo Ram KIM ; Jae Lim CHOI ; Ji Eun KIM ; Kwang Sook WOO ; Kyeoung Hee KIM ; Jeong Man KIM ; Sung Hyun KIM ; Jin Yeong HAN
Laboratory Medicine Online 2015;5(3):133-136
BACKGROUND: The automated hematologic analyzer has increased the precision and accuracy for platelet counting. However, spurious elevations of automated platelet counts occur occasionally in patients receiving chemotherapy or radiotherapy for solid organ tumors, leukemia, and other lymphomas. The CELL-DYN Sapphire analyzer (Abbott, USA) detects platelets with a CD61 monoclonal antibody and uses both impedance and optical technologies; thus, it is expected to present more accurate platelet counts. METHODS: We evaluated platelet counts obtained with the CELL-DYN Sapphire impedance, optical, and CD61 methods and compared them with the results obtained with the XE-2100 analyzer (Sysmex, Japan). We analyzed 111 samples from hospitalized patients with various hematologic diseases, who were receiving chemotherapy or radiotherapy. RESULTS: The results from the impedance, optical, and CD61 methods of CELL-DYN Sapphire and those from XE-2100 showed significant linearity, with correlation coefficients greater than 0.99. Three cases had significantly different platelet counts among the different methods used. Microscopic examination of these three cases showed very low platelet counts that corresponded with the low counts from the CD61 methods. It should be noted that because the automated blood counter assesses cell populations by their dimensions, many cellular fragments that were of the same size or smaller than platelets were thus counted as platelets. CONCLUSIONS: The CELL-DYN Sapphire analyzer has good precision, linearity and performance, comparable with the XE-2100 analyzer. As the CD61 methods of CELL-DYN Sapphire is specific for platelet, this method may reduce the interference from other blood components and count the exact platelet numbers.
Aluminum Oxide*
;
Blood Platelets
;
Drug Therapy*
;
Electric Impedance
;
Hematologic Diseases*
;
Humans
;
Leukemia
;
Lymphoma
;
Platelet Count*
;
Radiotherapy